ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

ASCO Highlights Seven of 4,000 Abstracts Submitted for Annual Meeting, June 3-7

May 27, 2011

In Brief: Gerald Dodd, Walter Lawrence Head ACS; Reauthorization Bills Expected Early ‘91

November 16, 1990

Hayloc, Krebs Lead Oncology Nurses

May 16, 1997

RFA For Patterns Of Care Study in Elderly Issues

January 14, 1983

Newell, Fredrickson Question Ethics Of Laetrile Trials

July 22, 1977

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

May 28, 2004